JTCS Sign the Guestbook
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Corcoran, P. C.
Right arrow Articles by Wallace, R. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Corcoran, P. C.
Right arrow Articles by Wallace, R. B.

The Journal of Thoracic and Cardiovascular Surgery, Vol 104, 66-72, Copyright © 1992 by The American Association for Thoracic Surgery and The Western Thoracic Surgical Association


ARTICLES

Platelet activating factor antagonist enhances lung preservation in a canine model of single lung allotransplantation

PC Corcoran, Y Wang, NM Katz, SS Rajan, AR Analouei, ML Foegh and RB Wallace
Department of Surgery, Georgetown University Medical Center, Washington, D.C. 20007.

Optimal techniques for lung preservation are yet to be defined. Platelet activating factor is a phospholipid released by a variety of cells and produces pulmonary abnormalities similar to posttransplantation pulmonary dysfunction. We investigated the strength of the effect of the platelet activating factor antagonist BN 52021 as compared with that of deferoxamine, an iron chelator previously shown to improve lung preservation. Differential lung function and pulmonary hemodynamics were used to assess preservation after a 6-hour period of cold ischemic storage in a modified canine model of left lung allotransplantation. Thirty size- and weight-matched mongrel male dogs were used for 15 transplant procedures randomized to one of three preservation techniques. The University of Wisconsin solution was used as the basic flush solution for all experimental animals. BN 52021 was added to the flush solution in one group (10 mg/kg, n = 5) and deferoxime in another group (10 mg/kg, n = 5). No additives were used for the control animals (n = 5). BN 52021 and deferoxime were administered to respective donor animals 30 minutes before organ harvesting (10 mg/kg) and to recipient animals 30 minutes before reperfusion (10 mg/kg). The pulmonary artery flush solution was administered (40 ml/kg) over 4 minutes. Recipient animals received double-lumen endotracheal tubes and were monitored with balloon-tipped, flow-directed catheters in both pulmonary arteries and dual-angle ultrasonic flow probes around each pulmonary artery. Solid-state high- fidelity micromanometers were used to measure pressures in the pulmonary artery, the left atrium, and the left ventricle. Systemic arterial, right and left pulmonary venous, and mixed venous blood samples were analyzed at 1, 2, 4, and 6 hours after transplantation. Pulmonary venous oxygen tension of the transplanted lung for the control group was 202 +/- 81 mm Hg versus 282 +/- 53 mm Hg for the BN 52021 group 6 hours after transplantation (p less than 0.05). Pulmonary vascular resistance of the transplanted lung for the control group was 319 +/- 54 dynes.sec.cm-5 versus 149 +/- 71 dynes.sec.cm-5 for the BN 52021 group (p less than 0.05). Proton magnetic resonance spectroscopy was performed on segments of upper and lower lobes of the native and transplanted lung from recipient animals to determine total lung water content. The BN 52021 group had a total lung water content of 57.3% as compared with 51.9% for the deferoxime group (p = not significant) and 88.6% for the control group (p less than 0.05).(ABSTRACT TRUNCATED AT 400 WORDS)


This article has been cited by other articles:


Home page
Eur. J. Cardiothorac. Surg.Home page
Y. A. B. Reyes, T. Shimoyama, H. Akamatsu, and M. Sunamori
MCI-186 (edaravone), a free radical scavenger, attenuates ischemia-reperfusion injury and activation of phospholipase A2 in an isolated rat lung model after 18 h of cold preservation
Eur. J. Cardiothorac. Surg., March 1, 2006; 29(3): 304 - 311.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
M. de Perrot, M. Liu, T. K. Waddell, and S. Keshavjee
Ischemia-Reperfusion-induced Lung Injury
Am. J. Respir. Crit. Care Med., February 15, 2003; 167(4): 490 - 511.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
J. D. Kim, C. J. Baker, R. F. Roberts, S. H. Darbinian, K. A. Marcus, S. M. Quardt, V. A. Starnes, and M. L. Barr
Platelet activating factor acetylhydrolase decreases lung reperfusion injury
Ann. Thorac. Surg., August 1, 2000; 70(2): 423 - 428.
[Abstract] [Full Text] [PDF]


Home page
Eur. J. Cardiothorac. Surg.Home page
S. Demertzis, F. Langer, T. Graeter, A. Dwenger, T. Georg, and H.-J. Schafers
Amelioration of lung reperfusion injury by L- and E- selectin blockade
Eur. J. Cardiothorac. Surg., August 1, 1999; 16(2): 174 - 180.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
K. Uthoff, K. J. Zehr, P. C. Lee, R. A. Low, W. A. Baumgartner, D. E. Cameron, and R. S. Stuart
Neutrophil Modulation Results in Improved Pulmonary Function After 12 and 24 Hours of Preservation
Ann. Thorac. Surg., January 1, 1995; 59(1): 7 - 13.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1992 by The American Association for Thoracic Surgery.